Cetirizine Hcl
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00341 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 20 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | allergic urticaria | KG + DL |
| 2 | cold urticaria | KG + DL |
| 3 | nasal cavity disease | KG + DL |
| 4 | acute laryngopharyngitis | KG + DL |
| 5 | rosacea conjunctivitis | KG + DL |
| 6 | recalcitrant atopic dermatitis | KG + DL |
| 7 | IgE responsiveness, atopic | KG + DL |
| 8 | angioedema | KG + DL |
| 9 | punctate epithelial keratoconjunctivitis | KG + DL |
| 10 | trigeminal autonomic cephalalgia | KG + DL |
| 11 | headache disorder | KG + DL |
| 12 | viral conjunctivitis | KG + DL |
| 13 | urticaria (disease) | KG + DL |
| 14 | Angelucci syndrome | KG + DL |
| 15 | chronic follicular conjunctivitis | KG + DL |
| 16 | parasitic conjunctivitis | KG + DL |
| 17 | conjunctival folliculosis | KG + DL |
| 18 | serous conjunctivitis except viral | KG + DL |
| 19 | acute hemorrhagic conjunctivitis | KG + DL |
| 20 | pseudomembranous conjunctivitis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.